Castle Biosciences Inc (CSTL) Becoming More Attractive for Investors

Castle Biosciences Inc’s recently made public that its Pres. & Chief Exec. Officer MAETZOLD DEREK J unloaded Company’s shares for reported $82997.0 on Mar 07 ’24. In the deal valued at $20.77 per share,3,996 shares were sold. As a result of this transaction, MAETZOLD DEREK J now holds 10,841 shares worth roughly $0.22 million.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Then, MAETZOLD DEREK J sold 2,372 shares, generating $49,266 in total proceeds. Upon selling the shares at $20.77, the Pres. & Chief Exec. Officer now owns 72,101 shares.

Before that, MAETZOLD DEREK J sold 4,131 shares. Castle Biosciences Inc shares valued at $88,461 were divested by the Pres. & Chief Exec. Officer at a price of $21.41 per share. As a result of the transaction, MAETZOLD DEREK J now holds 74,473 shares, worth roughly $1.49 million.

Guggenheim initiated its Castle Biosciences Inc [CSTL] rating to a Buy in a research note published on December 14, 2023; the price target was $25. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early January with a ‘”a Sector outperform”‘ rating. Stephens began covering CSTL with “an Overweight” recommendation on January 07, 2022. Lake Street started covering the stock on April 30, 2021. It rated CSTL as “a Buy”.

Price Performance Review of CSTL

On Tuesday, Castle Biosciences Inc [NASDAQ:CSTL] saw its stock fall -0.45% to $19.96. Over the last five days, the stock has lost -10.53%. Castle Biosciences Inc shares have fallen nearly -7.51% since the year began. Nevertheless, the stocks have risen 2.52% over the past one year. While a 52-week high of $26.70 was reached on 02/27/24, a 52-week low of $9.26 was recorded on 02/29/24. SMA at 50 days reached $22.10, while 200 days put it at $18.48. A total of 0.22 million shares were traded, compared to the trading of 0.39 million shares in the previous session.

Levels Of Support And Resistance For CSTL Stock

The 24-hour chart illustrates a support level at 19.60, which if violated will result in even more drops to 19.24. On the upside, there is a resistance level at 20.25. A further resistance level may holdings at 20.53. The Relative Strength Index (RSI) on the 14-day chart is 41.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.64, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.95%. Stochastics %K at 34.80% indicates the stock is a holding.

How much short interest is there in Castle Biosciences Inc?

A steep rise in short interest was recorded in Castle Biosciences Inc stocks on Feb 29, 2024, dropping by 30000.0 shares to a total of 1.21 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 1.24 million shares. There was a decline of -2.48%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.23% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.71.

The most recent change occurred on November 10, 2020 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $70 price target.

Most Popular